



GIAN LIFE CARE LIMITED

Regd Office:- 7/216 (6) Swaroop Nagar (Infront of L.L.R. Hospital), Kanpur, Uttar Pradesh-208002
CIN: U85100UP2018PLC110119; Mobile: 8808051576
Website: www.gianpathlabs.com;
Email: gpxreport@gmail.com

January 08, 2021

To,
Asst. General Manager
Dept of Corp. Services,
BSE Limited,
P.J. Towers, Dalal Street, Fort,
Mumbai: 400001.

Scrip Code:- 542918

Sub: Outcome of Board Meeting held on Friday, the 8th day of January, 2021

Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors at their meeting held today i.e.8th January, 2021, has *inter-alia* considered and approved the following:-

1. Standalone Financial Statements for the half-year ended 30th September, 2020. (Signed Copy along with Limited Review Report enclosed).

The Board Meeting commenced at 04:00 P.M and concluded at 05:30 P.M.



The above information shall also be made available on the website of the Company at www.gianpathlabs.com.

You are requested to kindly take the above information in your records.

Thanking You,

Yours faithfully,

For GIAN LIFE CARE LIMITED





(Arun Kumar Gupta)
Managing Director
DIN:- 01331593
Encl:- As above

Independent Auditor's Review Report on Half yearly unaudited Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Gian Life Care Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Gian Life Care Limited ("the Company") for the half year ended September 30, 2020 and year to date from April 01, 2020 to September 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5.Emphasis of Matter

We draw attention to Note 6 of the Statement, which describes the circumstances arising due to COVID-19, the uncertainties associated with its nature and duration and the consequential impact of the same on the financial results of the company.

Our conclusion on the statement is not modified in respect or the above matter.

For P.D.Dalal & Co.

Chartered Accountants

ICAI Firm Registration No.102047W


Aashish

(Aashish S. Kakaria)

Partner

Membership No.102915

UDIN : 21102915AAAAAA1502



Mumbai

08th January, 2021




UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Amount Rs. Lacs


Sr. No.	Particulars	Half Year Ended			For the Year Ended
		30.09.2020	31.03.2020	30.09.2019	31.03.2020
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	617.63	381.18	383.36	764.54
II	Other Income	13.90	5.70	4.38	10.08
III	Total Revenue(I+II)	631.53	386.88	387.75	774.62
IV	Expenses				
	(a) Cost of materials consumed	271.87	81.68	77.22	158.90
	(b) Employee benefits expense	44.77	44.29	62.51	106.80
	(c) Finance Cost	16.03	14.13	15.82	29.95
	(d) Depreciation and amortisation expense	14.11	13.08	12.43	25.51
	(e) Other Expenses	137.81	153.33	144.35	297.68
	Total Expenses	484.59	306.52	312.32	618.84
V	Profit before exceptional and extraordinary items and tax (III - IV)	146.94	80.36	75.43	155.78
VI	Exceptional Items	-	-	-	-
VII	Profit extraordinary items and tax (V - VI)	146.94	80.36	75.43	155.78
VIII	Extraordinary Items	-	-	-	-
IX	Profit before tax (VIII - VIII)	146.94	80.36	75.43	155.78
X	Tax Expenses :				
	(1) Current Tax	36.50	6.80	17.40	24.20
	(2) MAT Expenses	- 1.93	1.93	-	1.93
	(3) Tax of Previous Year	-	0.46	-	0.46
	(4) Deferred Tax	- 0.06	13.96	2.55	16.50
XI	Profit / (Loss) from Period from continuing optstions (VII -VIII)	112.43	57.21	55.48	112.69
XII	Profit (Loss) from discontinuing Operations	-	-	-	-
XIII	Tax Expense of Discontinuing operations	-	-	-	-
XIV	Profit / (Loss) from Discontinuing optstions (After Tax XII- XIII)	-	-	-	-
XV	Profit (Loss) for the period (XI +XIV)	112.43	57.21	55.48	112.69
XVI	Earnings Per Share of Rs. 10 Each (Not Annualised)				
	(a) Basic (Rs.)	2.39	1.59	1.69	3.13
	(b) Diluted (Rs.)	2.39	1.59	1.69	3.13

For Gian Life Care Limited,



(Dr. Arun Kumar Gupta)
 Managing Director
 (DIN NO:01331593)

Kanpur
 8-Jan-21




UNAUDITED STATEMENT OF ASSETS AND LIABILITIES AS ON 30.09.2020

Amount Rs.Lacs


Sr. No.	Particulars	Half Year Ended	Year Ended
		30.09.2020	31.03.2020
		Unaudited	Audited
1	Shareholders' Funds		
	(a) Share Capital	470.07	470.07
	(b) Reserves and Surplus	406.23	293.80
	©Money received against share warrants		
	Sub-total-Shareholders' Funds	876.30	763.87
2	Share application money pending allotment		
3	Non Current Liabilities		
	(a) Long Term Borrowings	68.66	75.12
	(b) Deferred Tax Liability	16.78	16.84
	Sub-total-Non Current Liabilities	85.43	91.96
4	Current Liabilities		
	(a) Short Term Borrowings	1.81	3.97
	(b) Trade Payables		
	Total outstanding dues of micro enterprises and small enterprises	-	-
	Total outstanding dues of creditors other than micro enterprises and small enterprises	158.42	110.94
	(c) Other Current Liabilities	272.36	240.44
	(d) Short Term Provisions	57.20	25.83
	Sub-total-Current Liabilities	489.79	381.18
	TOTAL EQUITY AND LIABILITIES	1,451.53	1,237.01
II	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible assets	304.46	281.24
	(ii) Intangible assets	2.37	2.72
	(b) Long Term Loans & Advances	640.19	543.63
	Sub-total-Non Current Assets	947.02	827.58
2	Current Assets		
	(a) Inventories	97.75	85.83
	(b) Trade Receivables	165.63	157.29
	(c) Cash & cash equivalents	186.95	112.77
	(d) Short Term Loans & Advances	13.94	7.57
	(e) Other Current Assets	40.23	45.98
	Sub-total-Current Assets	504.51	409.43
	TOTAL ASSETS	1,451.53	1,237.01

For Gian Life Care Limited,



(Dr. Arun Kumar Gupta)
Managing Director
(DIN NO:01331593)

Kanpur
8-Jan-21



CASH FLOW STATEMENT FOR THE HALF YEAR ENDED SEPTEMBER 30, 2020

Particulars		Half Year Ended 30-Sep-20 Rs.Lacs	Year Ended 31-Mar-20 Rs.Lacs
CASH FLOW FROM OPERATING ACTIVITIES			
Net profit before taxation		146.94	155.78
Adjustments for:			
Depreciation/ amortisation		14.11	25.51
Interest income		-13.90	-7.34
Interest expense		16.03	29.95
Operating profit before working capital adjustment		163.19	203.90
Changes in working capital:			
Inventories		-11.93	-1.89
Trade receivables		-8.34	-24.96
Loans & advances and other assets		-97.19	-40.62
Trade payables		47.47	9.82
Other liabilities and provisions		24.71	27.01
Cash flow generated from operations		117.91	173.25
Income tax paid (net of refunds)		0.00	-22.64
Net cash flow from operating activities	(A)	117.91	150.61
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of fixed assets (including intangible assets)		-36.99	-18.66
Interest received		13.87	7.21
Proceeds from Fixed Deposit		0.00	7.34
Proceeds from Takeover of business		0.00	0.00
Advances and loans made to third parties		0.00	-454.39
Receipts from the repayment of advances and loans made to third parties		0.00	62.23
Net Cash Flow from Investing Activities	(B)	-23.12	-396.28
CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from borrowing		0.00	27.74
Repayment of borrowings		-4.61	-53.80
Interest paid		-16.03	-29.95
Net Proceeds from issue of shares		0.00	311.48
Net Cash Flow From Financing Activities	(C)	-20.63	255.47
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)		74.16	9.80
Cash & Cash Equivalent at the beginning of the period		112.45	102.66
Cash & Cash Equivalent at the end of the period		186.61	112.45
Fixed deposits with banks		0.34	0.31
Cash and Bank Balances at the end of the period		186.95	112.77

for Kanpur



**Notes:**

1. The financial results were reviewed by the audit committee and approved by the Board of directors at its meeting held on 7th January 2021

2. The Company runs laboratories for carrying out pathological investigations.

3. As per AS 20 Earnings Per Share (EPS) issued by ICAI weighted average number of equity shares are used as the denominator in calculating basic and diluted earnings per share giving effect to Private Placement, Bonus Issue and Initial Public Offer.

4. There were no investor complaints received / pending as at 30th September, 2020

5. The company does not have more than one reportable segment in terms of AS-17 issued by ICAI. Hence segment wise reporting is not applicable.

6. On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and suggested guidelines for containment and mitigation worldwide. This has impacted the operations of the Company during the half year ended September 30, 2020. As at September 30, 2020, the Management has used internal and external sources of information upto the date of approval of these financial results in determining the impact of the COVID-19 pandemic. The Management has used the principles of prudence in developing estimates, assumptions, exercising judgements and performing sensitivity analysis. The eventual outcome of the impact of the pandemic may be different from that estimated as on the date of approval of these financial results. However the impact assessment of COVID-19 is a continuous process, given the uncertainties associated with its nature and duration. The Company will continue to monitor any material changes to future economic conditions and the consequent impact on its business, if any, and any significant impact of these changes would be recognized in the financial results as and when these material changes to economic conditions arise.

For Gian Life Care Limited,


(Dr. Arun Kumar Gupta)

Managing Director

(DIN NO:01331593)



Kanpur

8-Jan-21